FDA advisers to vote Tuesday on Merck’s COVID-19 pill even as interest has waned By: MarketWatch November 30, 2021 at 10:59 AM EST The advisory committee will decide whether the benefits of Merck’s experimental antiviral COVID-19 pill outweigh its risks. Read More >> Related Stocks: Eli Lilly Gilead Sciences Gsk Plc ADR Merck & Co Pfizer Regeneron Pharmaceuticals Vir Biotechnology Inc
